

May 1, 2019

Dan L. Bagatell
DBagatell@perkinscoie.com
D. +1.602.351.8250
F. +1.602.648.7150

BY ELECTRONIC FILING

The Honorable Scott S. Harris
Clerk of the Court
Supreme Court of the United States
One First Street, N.E.
Washington, D.C. 20543

Re: *Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc. et al.*, No. 18-1280

Dear Mr. Harris:

The petition for a writ of certiorari in this case was docketed on April 8, 2019, and responses and amicus briefs supporting the petition are currently due by May 8, 2019. Pursuant to Rule 30.4, respondents request that the Court extend the deadline to respond to the petition by 30 days to Friday, June 7, 2019.

The requested extension is necessary because respondents were recently advised that several entities intend to submit amicus briefs in support of the petition. The additional time will enable respondents to review the amicus briefs and take them into account in framing their responses to the petition.

I have conferred with counsel for the other respondents, and those respondents join in this extension request. Counsel for petitioner has advised that petitioner consents to this request.

Please let me know if you have any questions or concerns, and thank you for your consideration.

Respectfully submitted,

/s/Dan L. Bagatell

Dan L. Bagatell

Counsel for Respondent Mylan Pharmaceuticals Inc.

cc: T. Olson, counsel of record for petitioner
C. Klein, counsel for the Roxane and Teva respondents in the court of appeals